Morningstar

Bayer Files Lawsuit Against J&J, Alleging False Advertising for Prostate-Cancer Drug — Update

Provided by Dow Jones

By Nicholas G. Miller 




  Bayer filed a lawsuit against Johnson & Johnson and its Janssen Biotech unit, alleging that marketing claims regarding the superiority of J&J's Erleada prostate-cancer drug versus Bayer's Nubeqa are based on flawed data. 



  J&J said earlier this month that a study found that Erleada caused a 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer versus Nubeqa without the concurrent use of chemotherapy drug docetaxel. 



  Bayer said the claims are based on "scientifically flawed data and are not supported by a true head-to-head clinical trial." 



  The German company said J&J didn't adequately measure critical prognostic and baseline characteristics, such as non-cancer comorbidities, and that the patient population on Erleada in the analysis was five times the size of the group taking Nubeqa. 



  "Johnson & Johnson stands by the rigor and integrity of our real-world, head-to-head analysis," J&J said in a statement. 





  Write to Nicholas G. Miller at nicholas.miller@wsj.com. 





  (END) Dow Jones Newswires



  February 23, 2026 15:04 ET (20:04 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
5 Stocks to Buy Trading at Big Discounts
 
Plus, what recent bond market volatility means for investors. 
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
 
Defense spending and booming data center demand could provide powerful tailwinds for these 4-star stocks. 
 
 
David Sekera, CFA, Sarah Hansen, and Jess Bebel 
 
 
 
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
 
Despite a looming patent cliff, a strong drug pipeline and 4.1% yield give investors reasons for optimism. 
 
 
Karen Andersen, CFA 
 
 
 
What 7 Key Market Indicators Are Telling Investors Right Now
 
US equity valuations have retreated from their recent highs, but all 7 major market indicators remain above their long-term averages. 
 
 
Amy C. Arnott, CFA 
 
 
 
Don’t Overlook the Income Side of Fixed Income
 
Amid bond market tumult, elevated yields are contributing to returns and offering investors a nice income stream. 
 
 
Dan Lefkovitz 
 
 
 
 

			Sponsor Center